Last updated 2026-06-18
- Acquired by Menlo Therapeutics, Nov 2019
- Raised $64M funding round, Jul 2019
- Raised $16M funding round, Apr 2018
Total raised
$180.0M
Last: 2019-07
Stage
Public
Founded
2003
Headcount
52
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences
About
VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.
VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology and has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.
The company was formed from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.
Funding history · 2 rounds · $180.0M total
2019-07
$64.0M
2018-04
$16.0M
Q&A
- What is VYNE Therapeutics' primary focus?
- VYNE Therapeutics is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions.
- Which products has VYNE Therapeutics received FDA approval for?
- VYNE Therapeutics has received FDA approval for AMZEEQ (minocycline) topical foam, 4%, a topical minocycline; and ZILXI (minocycline) topical foam, 1.5%, a minocycline product for the treatment of rosacea.
- When was VYNE Therapeutics formed and how?
- VYNE Therapeutics was formed in November 2019 from the merger of Foamix, an Israeli clinical-stage specialty pharmaceutical company, and Menlo Therapeutics, a US-based dermatology company.
- What was the last funding round for VYNE Therapeutics?
- VYNE Therapeutics' last funding round was in July 2019, raising $64,000,000 from investors including Perceptive Advisors and OrbiMed.
- What is the employee count for VYNE Therapeutics?
- VYNE Therapeutics has 51-200 employees.
- Who is the founder of Foamix Pharmaceuticals, which merged to form VYNE Therapeutics?
- Meir Eini is the Founder of Foamix Pharmaceuticals.
- What is the current status of VYNE Therapeutics?
- VYNE Therapeutics is currently listed as acquired and inactive, having been acquired by Menlo Therapeutics in November 2019.
- What is VYNE Therapeutics' total amount raised in funding?
- VYNE Therapeutics has raised a total of $180,000,000 USD.
Team · 1
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
skin-caredermatologytopical-treatmentacnepharmaceuticalstreatmentspharma-companiespatientsinflammatory-diseases
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/68042510 | |
| facebook.com/VYNEtx | |
| Wikidata | wikidata.org/wiki/Q104480752 |
Identifiers & details
| Former names | Foamix Pharmaceuticals, Menlo Therapeutics |
|---|---|
| Founded | 2003-1 |
| Employees (exact) | 52 |
| Offices | Bridgewater Township |
| Market cap | $19.3M |
| Status reason | Acquired (Inactive) by Menlo Therapeutics on Nov 2019 - ceased to operate |
| Wikidata QID | Q104480752 |
Acquisitions & public offerings
Acquired by Menlo Therapeutics 2019-11
Radar intelligence
Patents
| EPO | 16 |
|---|
Wikidata
| QID | Q104480752 |
|---|